Status:
COMPLETED
Cathelicidin LL-37 Relation to Potentially Malignant Lesions
Lead Sponsor:
Fayoum University
Collaborating Sponsors:
Cairo University
Conditions:
Oral Potentially Malignant Lesions
Eligibility:
All Genders
30-70 years
Brief Summary
LL-37 appears to have a potential role in potentially malignant lesions (OLP \& leukoplakia). The remarkable diagnostic accuracy of salivary LL-37 in differentiating potentially malignant lesion and h...
Detailed Description
Aim: The recognition of practical early diagnostic biomarkers is a cornerstone of improved prevention and treatment of cancer thus the current study estimated salivary level of Cathelicidin LL-37 in p...
Eligibility Criteria
Inclusion
- Both genders with age range 30 - 70 years.
- Patients agreed to sign a written consent after understanding the nature of the study.
- Clinically diagnosed and histologically confirmed as having oral potentially malignant lesions mainly atrophic/erosive oral lichen planus and oral leukoplakia.
Exclusion
- Systemic diseases as well as pregnant or lactating females.
- Patients currently taking corticosteroids, immunosuppressives drugs, contraceptive pills, or antibiotics.
- Patients are diagnosed with any other oral lesions other than oral lichen planus and oral leukoplakia.
- Vulnerable subjects as prisoners, or mentally disabled.
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 15 2023
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06219330
Start Date
July 1 2023
End Date
November 15 2023
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sandy hassan shaaban
Cairo, Egypt